The tumour microenvironment as an integrated framework to understand cancer biology

Fecha de publicación: Fecha Ahead of Print:

Autores de INCLIVA

  • Rebeca Burgos Panadero

    Autor

  • Federico Lucantoni

    Autor

  • Esther Gamero Sandemetrio

    Autor

Participantes ajenos a INCLIVA

  • de la Cruz-Merino, L
  • Alvaro, T

Grupos y Plataformas de I+D+i

Abstract

Cancer cells all share the feature of being immersed in a complex environment with altered element communication, physicochemical information, and tissue functions. The so-called tumour microenvironment (TME) is becoming recognised as a key factor in the genesis, progression and treatment of cancer lesions. Beyond genetic mutations, the existence of a malignant microenvironment forms the basis for a new perspective in cancer biology where connections at the system level are fundamental. From this standpoint, different aspects of tumour lesions such as morphology, aggressiveness, prognosis and treatment response can be considered under an integrated vision, giving rise to a new field of study and clinical management. Nowadays, somatic mutation theory is complemented with study of TME components such as the extracellular matrix, immune compartment, stromal cells, metabolism and biophysical forces. In this review we examine recent studies in this area and complement them with our own research data to propose a classification of stromal changes. Exploring these avenues and gaining insight into malignant phenotype remodelling, could reveal better ways to characterize this disease and its potential treatment.

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/)

Datos de la publicación

ISSN/ISSNe:
0304-3835, 1872-7980

CANCER LETTERS  ELSEVIER IRELAND LTD

Tipo:
Review
Páginas:
112-122
PubMed:
31325528

Citas Recibidas en Web of Science: 74

Documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Biophysics; Bioelectric; Metabolism; Cancer treatment; Extracellular matrix; Stromal classification

Financiación

Proyectos y Estudios Clínicos

INCORPORACIÓN DE NUEVAS ÁREAS TEMÁTICAS Y NUEVOS GRUPOS AL CONSORCIO CIBER

Investigador Principal: ROSA NOGUERA SALVA

CB16/12/00484 . INSTITUTO SALUD CARLOS III

Identificación y validación de nuevas terapias, modelos preclínicos y marcadores de respuesta terapéutica en neuroblastoma. (PI17/01558).

Investigador Principal: ROSA NOGUERA SALVA

PI17/01558 . INSTITUTO SALUD CARLOS III . 2018

Cita

Compartir